Novo Nordisk's CagriSema Tops Low-Dose Tirzepatide in Late-Stage Diabetes Trial
核心洞察
Novo Nordisk reported that CagriSema produced an estimated 12.4% body weight loss versus 9.1% for patients receiving Eli Lilly's tirzepatide in a late-stage diabetes study.
The trial tested tirzepatide at its 5-milligram dose rather than higher approved doses, and enrolled people with diabetes, limiting how the headline gap can be interpreted.
Novo Nordisk also reported non-inferior blood-sugar reduction for CagriSema against the Lilly comparator in the same study.
Novo Nordisk said its investigational combination CagriSema outperformed Eli Lilly's tirzepatide at the 5-milligram dose in a late-stage study conducted in people with diabetes, according to data reported Monday. Patients taking CagriSema lost an estimated 12.4% of their body weight, compared with 9.1% for those receiving the Lilly comparator, while Novo Nordisk also reported non-inferior blood-sugar reduction.
Trial Design Limits the Head-to-Head Readout
The comparison carries a significant caveat. The study enrolled people with diabetes rather than an obesity (搜索)-only population, and tirzepatide was tested at 5 milligrams rather than at its higher approved doses. Those two design features make the headline percentage gap less straightforward than it first appears, since the dose and patient population differ from the settings in which tirzepatide is used at scale.
The result follows an earlier head-to-head trial in which CagriSema lost to Zepbound in an obesity (搜索)-focused setting. Taken together, the two datasets indicate that dosage, patient population and eventual real-world adoption matter more than any single low-dose comparison.
Regulatory Timing and Competitive Position
Novo Nordisk expects a US Food and Drug Administration decision on CagriSema for weight management in the fourth quarter. That pending review keeps competitive pressure on the obesity (搜索) and diabetes franchise, though the commercial question for Novo Nordisk is whether an approval translates into meaningful pricing power and market share.
For Eli Lilly, the readout is the latest competitive data point in a market where both companies are advancing incretin-based therapies across diabetes and obesity (搜索) indications. The company's larger exposure remains its approved tirzepatide franchise, which was represented in this study only by the 5-milligram dose.